Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is an innovative clinical-stage biotech company with a promising product pipeline, including GRI-0621, a small molecule RAR-beta and gamma dual agonist for the treatment of diseases associated with dysregulated immune responses. With positive top-line data in December 2025 and a current Phase 2a trial in patients with IPF, the company's potential for success in this large market is attractive. In addition, the recent Q3 results show strong financial management and potential for continued growth.

Bears say

GRI Bio is a clinical-stage biotech company with potential drugs targeting multiple serious diseases, but the current valuation is attractive due to long development and commercialization timelines and the company's financials are not yet generating any revenue. While the company's two drugs present high risks, their estimated billion-dollar market potential makes them attractive long-term investments in the autoimmune and inflammatory disorder space, especially their lead candidate GRI-0803 which aims to treat the estimated 1.5 million Americans with lupus.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.